Endpoints in sepsis trials: More than just 28-day mortality?
- 1 May 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (Supplement) , S209-S213
- https://doi.org/10.1097/01.ccm.0000126124.41743.86
Abstract
To determine whether an intervention, either therapeutic or diagnostic, is effective, it needs to be assessed according to a predefined endpoint (or outcome measure), the choice of which will vary according to the aims of the study in question and the anticipated effects of the intervention being tested. Studies can have one of several functions (which are not always mutually exclusive), including providing evidence of biological efficacy, determining a clinically important benefit, and achieving regulatory approval. In trials of therapeutic efficacy in sepsis, mortality rates are a good endpoint because death is common and mortality rates are an unambiguous measure: patients either survive or they do not. However, the time at which mortality should be recorded is less clear cut, and this single endpoint provides no information regarding the biological activity or disease modification effects of the agent under investigation. In this article, we will briefly discuss some of the potential alternative endpoints that could be used in the assessment of antisepsis agents.Keywords
This publication has 26 references indexed in Scilit:
- Quality of life six years after intensive careIntensive Care Medicine, 2003
- Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*Critical Care Medicine, 2003
- One-Year Outcomes in Survivors of the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2003
- A four-step protocol for limitation of treatment in terminal care. An observational study in 475 intensive care unit patientsIntensive Care Medicine, 2002
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patientsCritical Care Medicine, 2001
- Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsisCritical Care Medicine, 1998
- Magnitude and Duration of the Effect of Sepsis on SurvivalJAMA, 1997
- The Effects of Ibuprofen on the Physiology and Survival of Patients with SepsisNew England Journal of Medicine, 1997
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996